214 related articles for article (PubMed ID: 33389590)
21. Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment.
Yamashige D; Kawamura Y; Kobayashi M; Shindoh J; Kobayashi Y; Okubo S; Muraishi N; Kajiwara A; Iritani S; Fujiyama S; Hosaka T; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Ikeda K; Arase Y; Hashimoto M; Kumada H
Oncology; 2021; 99(3):169-176. PubMed ID: 33207358
[TBL] [Abstract][Full Text] [Related]
22. Interstitial pneumonia suspected during regorafenib administration and exacerbated by subsequent therapy with lenvatinib for unresectable hepatocellular carcinoma.
Kotani K; Enomoto M; Okada M; Yoshida K; Motoyama H; Fujii H; Hagihara A; Uchida-Kobayashi S; Morikawa H; Murakami Y; Tamori A; Kawada N
Clin J Gastroenterol; 2019 Aug; 12(4):355-360. PubMed ID: 31020569
[TBL] [Abstract][Full Text] [Related]
23. Low-dose steroid-induced tumor lysis syndrome in a hepatocellular carcinoma patient.
Kim JO; Jun DW; Tae HJ; Lee KN; Lee HL; Lee OY; Choi HS; Yoon BC; Hahm JS
Clin Mol Hepatol; 2015 Mar; 21(1):85-8. PubMed ID: 25834806
[TBL] [Abstract][Full Text] [Related]
24. [Preclinical study for antitumor mechanism of lenvatinib and clinical studies for hepatocellular carcinoma].
Watanabe T; Koyama N
Nihon Yakurigaku Zasshi; 2019; 153(5):242-248. PubMed ID: 31092758
[TBL] [Abstract][Full Text] [Related]
25. Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma.
Koizumi Y; Hirooka M; Hiraoka A; Ochi H; Tanaka T; Yukimoto A; Imai Y; Watanabe T; Yoshida O; Miyake T; Matsuura B; Michitaka K; Joko K; Abe M; Hiasa Y
Endocr J; 2019 Sep; 66(9):787-792. PubMed ID: 31142692
[TBL] [Abstract][Full Text] [Related]
26. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
Fu R; Jiang S; Li J; Chen H; Zhang X
Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
[TBL] [Abstract][Full Text] [Related]
27. [A case of advanced hepatocellular carcinoma wherein readministration was made possible due to successful transcatheter arterial embolization for intratumoral hemorrhage during Lenvatinib administration].
Hara H; Nakano Y; Arai K; Kaneko Y; Sakaki K; Fukami Y; Ikemiyagi H; Yoshino K; Sakita S
Nihon Shokakibyo Gakkai Zasshi; 2022; 119(5):476-485. PubMed ID: 35545547
[TBL] [Abstract][Full Text] [Related]
28. FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma.
Nair A; Reece K; Donoghue MB; Yuan WV; Rodriguez L; Keegan P; Pazdur R
Oncologist; 2021 Mar; 26(3):e484-e491. PubMed ID: 33044793
[TBL] [Abstract][Full Text] [Related]
29. Development of a thrombus in the superior mesenteric artery associated with sequential therapy with tyrosine kinase inhibitors for hepatocellular carcinoma.
Nawa T; Katayama K; Kiyota R; Imai T; Abe Y; Hasegawa N; Takada R; Fukutake N; Ikezawa K; Sakakibara M; Fujita M; Ohkawa K
Clin J Gastroenterol; 2020 Apr; 13(2):247-251. PubMed ID: 31317371
[TBL] [Abstract][Full Text] [Related]
30. [A Case of Advanced Hepatocellular Carcinoma That Caused Rapid Re-Growth Due to Lenvatinib Withdrawal].
Oyama K; Maeda S; Nakahira S; Kitagawa A; Ushimaru Y; Ohara N; Miyake Y; Makari Y; Nakata K; Fujita J
Gan To Kagaku Ryoho; 2021 Dec; 48(13):1586-1588. PubMed ID: 35046264
[TBL] [Abstract][Full Text] [Related]
31. [A Case of Unresectable Hepatocellular Carcinoma Treated using Lenvatinib and Conversion Surgery].
Utsunomiya T; Sakamoto K; Iwata M; Ito C; Sakamoto A; Matsui T; Shine M; Nishi Y; Uraoka M; Nagaoka T; Tamura K; Funamizu N; Ogawa K; Kitazawa R; Takada Y
Gan To Kagaku Ryoho; 2022 Dec; 49(12):1365-1367. PubMed ID: 36539251
[TBL] [Abstract][Full Text] [Related]
32. Hepatocellular Carcinoma Rupture after Introducing Lenvatinib: An Autopsy Case Report.
Kohya R; Sugiura R; Yamamoto Y; Naruse H; Hatanaka K; Kinoshita K; Abiko S; Miyamoto S; Suzuki K; Kushibiki H; Munakata S; Shimoyama N
Intern Med; 2023 Apr; 62(7):995-998. PubMed ID: 36047124
[TBL] [Abstract][Full Text] [Related]
33. Repeated Perforation of the Gallbladder in a Patient with Hepatocellular Carcinoma Receiving Lenvatinib.
Honda S; Saito Y; Sawada K; Hasebe T; Nakajima S; Okumura T
Intern Med; 2020 Mar; 59(5):657-662. PubMed ID: 31735795
[TBL] [Abstract][Full Text] [Related]
34. Lenvatinib-Induced Tumor-Related Hemorrhages in Patients with Large Hepatocellular Carcinomas.
Uchida-Kobayashi S; Kageyama K; Yamamoto A; Ikenaga H; Yoshida K; Kotani K; Kimura K; Odagiri N; Hagihara A; Fujii H; Enomoto M; Tamori A; Kubo S; Miki Y; Kawada N
Oncology; 2021; 99(3):186-191. PubMed ID: 33032274
[TBL] [Abstract][Full Text] [Related]
35. Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment.
Chuma M; Yokoo H; Hiraoka A; Ueda K; Yokoyama T; Tsuji K; Shimada N; Uojima H; Kobayashi S; Hattori N; Okubo T; Atsukawa M; Ishikawa T; Takaguchi K; Tsutsui A; Toyoda H; Tada T; Saito Y; Hirose S; Tanaka T; Takeda K; Otani M; Sekikawa Z; Watanabe T; Hidaka H; Morimoto M; Numata K; Kagawa T; Sakamoto M; Kumada T; Maeda S
Curr Oncol; 2022 May; 29(5):3259-3271. PubMed ID: 35621656
[TBL] [Abstract][Full Text] [Related]
36. Obstructive Jaundice Due to Duodenal Ulcer Induced by Lenvatinib Therapy for Hepatocellular Carcinoma.
Suoh M; Hagihara A; Yamamura M; Maruyama H; Taira K; Enomoto M; Tamori A; Fujiwara Y; Kawada N
Intern Med; 2021 Feb; 60(4):545-552. PubMed ID: 33028766
[TBL] [Abstract][Full Text] [Related]
37. Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma.
Ikeda A; Aoki K; Kawamura M; Yamaguchi D; Kokuryu H
Intern Med; 2021; 60(3):403-407. PubMed ID: 33518611
[TBL] [Abstract][Full Text] [Related]
38. Incidental tumor necrosis caused by the interventional alteration of hepatic arterial flow in patients with advanced hepatocellular carcinoma.
Suzuki E; Ooka Y; Chiba T; Kobayashi K; Kanogawa N; Motoyama T; Saito T; Ogasawara S; Tawada A; Yokosuka O
Clin J Gastroenterol; 2015 Feb; 8(1):41-6. PubMed ID: 25481841
[TBL] [Abstract][Full Text] [Related]
39. Sorafenib
Kuzuya T; Ishigami M; Ito T; Ishizu Y; Honda T; Ishikawa T; Fujishiro M
Anticancer Res; 2020 Apr; 40(4):2283-2290. PubMed ID: 32234927
[TBL] [Abstract][Full Text] [Related]
40. Conversion Hepatectomy for Huge Hepatocellular Carcinoma With Arterioportal Shunt After Chemoembolization and Lenvatinib Therapy.
Sato N; Beppu T; Kinoshita K; Yuki H; Suyama K; Chiyonaga S; Motohara T; Komohara Y; Hara A; Akahoshi S
Anticancer Res; 2019 Oct; 39(10):5695-5701. PubMed ID: 31570469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
